AdnaGen enters into agreement to license antibodies to KellBenx
AdnaGen, a subsidiary of OncoVista Innovative Therapies, a biotechnology company, has entered into an option agreement to license specific antibodies to KellBenx, a New York-based biotech firm.
Incyte Corporation announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: